-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: What are the features of the CDX platform?
Author:
InnoModels
Release time:
2024-06-06
With the rapid development in the field of biomedicine, cancer research and treatment has entered a brand new era. In this era, an efficient and precise experimental platform has become the key for scientists to overcome cancer. The InnoModels Biotechnology CDX platform was born out of necessity, and with its unique features and advantages, it is gradually becoming a new favorite in the field of cancer research and treatment.
First of all, InnoModels Biotechnology CDX platform has a huge tumor cell line library. This platform brings together more than 400 different tumor cell lines, covering a wide range of cancer types and subtypes. This diverse library of tumor cell lines provides researchers with a wealth of choices, enabling them to select the most appropriate cell line for a specific research area. This flexibility ensures the depth and breadth of research and provides a solid foundation for precision cancer treatment.
Secondly, the InnoModels CDX platform focuses on preserving the original heterogeneity. By maintaining the heterogeneity of the original cancer tissue, the platform enables researchers to gain a more comprehensive understanding of the complex characteristics of tumors. This heterogeneity is critical in cancer research because it helps reveal the mechanisms of tumorigenesis, progression and metastasis. Through the CDX platform, scientists can delve into the biology of tumor cells, providing a more accurate data base for precision medicine.
Furthermore, the InnoModels CDX platform is highly portable, and the high portability of CDX graft tumors in animals makes it an ideal tool for drug discovery and development. Through the CDX platform, researchers can simulate the growth and spreading process of human tumors in animals, so as to evaluate the therapeutic effects of different drugs on tumors. This feature provides a fast and efficient experimental tool for drug development and accelerates the process of new drug development.

In addition, InnoModels' CDX platform is widely used in the research of various cancer types. Whether it is breast cancer, lung cancer or colorectal cancer, etc., the platform can provide strong support for researchers. This wide range of applications makes the CDX platform a bridge for interdisciplinary cancer research and promotes synergistic collaboration between different fields.
It is worth noting that the InnoModels Biotechnology CDX platform also excels in data integrity and regulatory compliance. The platform maintains thorough and traceable experimental records, making research data more reliable and credible. This provides researchers with a strong guarantee that their studies will comply with industry standards and regulatory requirements.
In summary, with its large tumor cell line library, ability to preserve original heterogeneity, high portability, and wide range of applications, the InnoModels Biotechnology CDX platform shows strong potential in the field of cancer research and treatment. The platform provides scientists with an efficient and precise experimental platform, offering new hope for overcoming the worldwide challenge of cancer. In the future, with the continuous progress and innovation of the technology, the InnoModels Biotechnology CDX platform will continue to fulfill its unique advantages and bring more breakthroughs and achievements in the field of cancer research and treatment.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd